Who Owns Your Supplement Formula?

You can pay for every hour of formulation, put your brand on the bottle, and sell the product for years, and still not own the formula inside it. That surprises a lot of capable operators, because it runs against a fair assumption: I paid for it, so it’s mine.

Ownership of a supplement formula doesn’t work that way by default. It’s decided by what your agreement says and by which documents you actually hold. The gap between “I paid for it” and “I own it, and I can make it somewhere else” is where brands get locked in, usually without noticing until the day they want to move.

The trap is avoidable, and it mostly comes down to knowing what “the formula” is really made of and asking a few plain questions before you commit. This is an educational overview, not legal advice, but it should tell you what to take to your counsel.

Educational overview: not legal, regulatory, or medical advice. Requirements change and vary by jurisdiction and sales channel. Last reviewed July 2026.

Short answer. “Who owns the formula?” is really three questions: who holds the recipe (the ingredients and amounts), who holds the manufacturing record (the build), and who holds the legal right to use it somewhere else. A supplement formula is usually protected as a trade secret, so ownership follows your written agreement, not the fact that you paid. Line up all three layers and your product can move. Miss one and it can be locked in place.

Best for: Brand owners choosing a manufacturing path, and existing brands planning a switch.

Key decision: Whether your agreement assigns the formula to you, licenses it, or leaves it as the manufacturer’s, and whether you’ll receive documentation complete enough to reproduce the product elsewhere.

Apollo path: A custom formula developed to your brief and paid for is yours, with the documentation to reproduce it. Your counsel sets the ownership terms; Apollo executes the manufacturing.

Three things people call “your formula,” and why the difference decides everything

When someone asks “do I own my formula,” they usually mean one thing and need to be asking about three. Pull them apart and the whole question gets clearer.

The recipe: the “what.” The ingredient identities and their amounts. This is what most people picture when they say “the formula.” It’s necessary, but on its own it’s the least of the three, because much of it is legible on your own label. A Supplement Facts panel already lists your dietary ingredients; anyone can read them. The part that’s genuinely yours to protect is rarely the ingredient names.

The manufacturing record: the “how.” This is the build: the order of addition, mixing and processing parameters, any intentional overage that keeps the product on-claim through its shelf life, the flavor-masking system, the preservation and pH strategy in a liquid. This is what actually lets someone reproduce your product and have it come out the same. In a cGMP facility this lives in the master manufacturing record; under 21 CFR 111.210 (current as of mid-2026), a manufacturer has to write down the components, the exact weights and measures, any overage, the expected yield at each step, and the step-by-step instructions. The record exists. The question is whether you’re entitled to a copy of it.

The legal right: the “may I.” Whether you own the formula outright or merely have permission to use it, and whether you can make it somewhere other than the shop that developed it. This one is set entirely by your written agreement, and it’s the layer people skip.

You can hold any one of these without the others: own the recipe but not the manufacturing record, or hold both documents and still be contractually barred from using them elsewhere. Portability (actually making your product at another manufacturer) needs all three to line up.

“I paid for it, so I own it” is the wrong mental model

The instinct is reasonable and the conclusion is often wrong. Paying for development doesn’t, by itself, make you the owner of what gets developed. To see why, it helps to know which kind of intellectual property a supplement formula actually is, because people reach for the wrong one.

It is usually a trade secret. A formula that isn’t published and gives you a competitive edge is protected, if at all, as a trade secret. The federal Defend Trade Secrets Act defines a trade secret (18 U.S.C. § 1839, as of mid-2026) as information whose owner “has taken reasonable measures to keep such information secret” and that “derives independent economic value” from not being generally known. Two things follow. First, trade-secret protection tracks who developed the information and who guards it, not who paid the invoice, unless a contract says otherwise. Second, the same statute says “improper means” of acquiring a trade secret specifically excludes “reverse engineering, independent derivation, or any other lawful means.” Trade-secret law, in other words, does not by itself stop anyone from reverse-engineering a product they lawfully bought. When a private-label product is hard to move, the restriction is almost always contractual, not a feature of trade-secret law.

It is not a copyright, so “work made for hire” is the wrong frame. People invoke “work for hire” to argue that because they commissioned the work, they own the result. Work made for hire is a copyright concept. Under 17 U.S.C. § 101 (as of mid-2026) it covers a work an employee prepares within the scope of employment, or a work “specially ordered or commissioned” that falls into one of nine listed categories: a contribution to a collective work, part of a motion picture, a translation, a supplementary work, a compilation, an instructional text, a test, answer material for a test, or an atlas. A functional formula is on none of that list, and a list of ingredients isn’t the kind of creative expression copyright protects in the first place. So the “work for hire” argument doesn’t reach your formula. Copyright may protect your label artwork and your marketing copy; it does not hand you the recipe.

It is occasionally a patent. A composition or method can be patented, but few supplement formulas are; a patent trades secrecy for a public disclosure and a fixed term, and most brands would rather keep the know-how quiet. Where a patent exists, ownership starts with the inventor and moves only by a written instrument: 35 U.S.C. § 261 (as of mid-2026) provides that patents and applications “shall be assignable in law by an instrument in writing.” Paying for the work is not the instrument.

The through-line across all three: absent a written assignment, the party that developed the formula can end up owning it, even when you funded the development. That’s not a manufacturer being sneaky. It’s the default. Which is exactly why the written terms matter more than the invoice, and why this is a conversation to have with your counsel before development starts, not after.

Assignment vs. license: the distinction that decides what you can do

Two words do most of the work in a formula-ownership clause, and they are not interchangeable.

An assignment transfers ownership. After an assignment, the formula is yours; the manufacturer holds no title to it. A license grants permission to use, while the manufacturer keeps title. A license can be narrow or broad, exclusive or non-exclusive, permanent or time-limited, revocable or not. A non-exclusive license means the manufacturer can license the same formula to someone else, including a competitor. An exclusive license can look almost like ownership until the manufacturer is sold, goes under, or reaches the end of the term, and the right you were relying on changes hands or lapses.

For a brand, the practical test is simple: what can you still do the day the relationship ends badly? With an assignment, you keep the formula and move on. With a license, you keep only what the license lets you keep, which may be nothing.

Which one you get isn’t a detail to sort out later. It’s the difference between an asset you own and a permission you rent, and it is decided in writing before the first bench batch is mixed. What belongs in that writing is your counsel’s call, not your manufacturer’s.

Ownership by path: stock, private label, and custom from the bench

How much of this you even need to worry about depends on the path you take to a product. There are three, and they carry very different ownership defaults.

A stock or white-label base is a formula the manufacturer already makes and owns. You put your brand on it and go to market fast, but you don’t own the formula and generally can’t take it anywhere; there’s nothing of yours to take. That’s not a trap; it’s the deal, and often the right one for a first product. It becomes a problem only when nobody told you that’s what you were buying.

Private label with light customization is where most surprises live. You start from the manufacturer’s base and adjust a flavor, a color, a dose, and who owns the result depends entirely on the agreement. Often the base stays theirs and the tweaks are yours in name only; sometimes the modifications are assigned to you but the underlying formula never is. Reproducing “your” product elsewhere can be impossible, because the part that makes it work was never yours.

A custom formula from the bench is developed to your brief. This is the path where ownership is worth fighting for and worth getting in writing, because there’s a real, movable asset at the end of it. If your agreement assigns the formula to you and you paid for the development, it can be yours: recipe, record, and the right to make it wherever you choose.

None of these paths is wrong. They’re different trades between speed, first commitment, differentiation, and whether you walk away owning something. If you’re weighing the paths themselves, the companion piece White Label, Private Label, or Custom Formula: Which Path Fits Your Supplement lays them side by side. The ownership point here is narrower: the more custom the work, the more there is to own, and the more it matters that the agreement actually gives it to you.

How a formula gets locked in: the portability trap

“Locked in” rarely happens through one dramatic clause. It’s usually the quiet accumulation of small gaps, each defensible on its own, that together mean you can’t leave with your product. The common ones:

• You only ever see a proprietary blend. Your Supplement Facts panel can legally show a blend’s total weight without breaking out each ingredient’s amount, and there are good reasons a manufacturer keeps exact ratios off the public label; the Supplement Facts panel rules cover how that’s done. The trap is when your own agreement never gives you the ratios either. You can’t reproduce a product whose amounts you’ve never been shown.
• The manufacturing record stays behind. You’re handed a one-line “formula sheet” but not the build: no overages, no in-process specs, no order of addition. Another manufacturer can’t run from that, so in practice you can’t move, even if the recipe is nominally yours.
• The contract assigns the IP to the manufacturer. Sometimes plainly, sometimes buried in a definitions section as “proprietary to Manufacturer.” Whatever you developed together becomes theirs by the terms you signed.
• A release fee gates your files. The documents exist, but a fee (sometimes a large one) stands between you and a portable copy. This is where “we’ll sort ownership later” becomes expensive.
• A restriction bars you from making it elsewhere. Recall that trade-secret law itself doesn’t forbid reverse engineering a product you lawfully bought. A contract can forbid it anyway, along with barring you from using the formula with any other manufacturer. That’s a portability restriction, and it can bind you even when you nominally “own” the formula.

There’s a compliance wrinkle that makes lock-in worse. The firm whose name and address sit on the label (the own-label distributor) carries the regulatory weight for the product, even though a contractor makes it. FDA’s dietary supplement cGMP guidance (as of mid-2026) states that an own-label distributor has “an obligation to know what and how manufacturing activities are performed” and bears “overarching and ultimate responsibility” for compliance. So you can be the party FDA holds accountable while not holding the record of how the product is actually made, a strong reason to insist on the means to reproduce it.

The documentation that makes a formula portable

Ownership on paper is only half of it. What lets you actually move is the documentation in your possession. Here’s what to make sure you receive, and why each item matters:

• The full ingredient list with exact amounts or percentages: every component, not a proprietary-blend summary. You can’t reproduce what you can’t see.
• The finished-product specification: what the product must test to for identity, potency, and contaminant limits. This is the target any future manufacturer has to hit.
• A manufacturing record you can actually use. Master-manufacturing-record-level detail: order of addition, mixing and processing parameters, any intentional overage, the flavor-masking and preservation systems. Under 21 CFR 111.210 the manufacturer builds this record as a matter of cGMP; the open question is whether you’re entitled to a portable copy.
• Per-lot Certificates of Analysis from qualified third-party labs, so a new partner and your marketplace can see the product’s real history.
• The written ownership terms: whether the agreement assigns the formula to you or licenses it, and on what conditions.
• A plain statement of what is yours to take if the relationship ends: formula, records, custom components, and tooling included.

One reassuring fact and one caution. The reassuring fact: the record of how your product was made exists somewhere. Under 21 CFR 111, a manufacturer has to keep its master manufacturing record and batch production records for a defined period: as of mid-2026, at least one year past the shelf-life date if shelf-life dating is used, or two years beyond the date the last batch was distributed (21 CFR 111.605). The caution: records existing is not the same as you receiving them. Whether a portable copy comes to you is a commercial and contract question, and it’s far easier to settle before development than after a dispute. If you’re assembling what to bring to a manufacturer conversation, How to Prepare for a Manufacturing Quote covers how to stage sensitive detail behind an NDA before you share it.

Why ownership becomes decisive the day you switch

For most brands, formula ownership stays abstract right up until the moment it isn’t, and that moment is a transfer. The current manufacturer gets slow, or rigid on minimums, or a quality problem shakes your confidence, and you decide to move. That’s when all three layers get tested at once: do you own it, do you hold the record, and are you contractually free to make it elsewhere?

Line them up and a switch is orderly. You own the formula, you hold a manufacturing record another shop can run from, and nothing bars you from moving, so a new manufacturer starts from a benchmark sample and a spec review, not a blank page. That’s the premise of a clean transfer, and what the Manufacturer Transfer Playbook walks through.

Miss a layer and the same switch turns into a standing start. No exact amounts means reverse-engineering your own product. No manufacturing record means re-developing the build and re-running stability. A restrictive contract means negotiating (or paying a release fee) before you can begin. The time to prevent that isn’t the week you decide to leave; it’s before you sign the agreement that governs the work.

Apollo’s position on ownership and portability

Apollo Future Labs states its position up front, because in this industry transparency is the differentiator. A custom formula developed to your brief and paid for is your brand’s, and you receive the documentation to reproduce it: the ingredient detail and the manufacturing record, not a one-line summary. The intent is the opposite of holding a formula as leverage: a partner worth staying with earns it by keeping up, not by making it impossible to leave.

Materials follow the same rule as everything else on the floor. Custom components remain buyer-owned unless agreed otherwise in writing, disclosed before you commit rather than discovered on an invoice, the same upfront-disclosure logic behind Component Minimums vs. Finished Runs. What’s yours is yours, and it’s written down.

That last part is the point, and the boundary. This posture only means anything because it’s in the agreement, which is where your counsel comes in. Apollo executes the manufacturing and hands over the documentation from its FDA-registered, cGMP-compliant facility in Livermore, California. Your attorney decides the ownership and portability terms that fit your business. Apollo supports the execution; your counsel decides the strategy.

Questions that reveal who really owns your formula

You can’t tell where you stand from a friendly conversation. These questions pull it into the open. Bring them to any manufacturer, Apollo included, and take the answers to your counsel.

• Is this a stock or private-label formula, or one developed specifically for my brand? Separates renting a formula from owning one.
• Does our agreement assign the formula to me, or license it to me? Assignment makes you the owner; a license leaves the title with them and can be narrowed, revoked, or shared with others.
• Will I receive the exact amount of every ingredient, or only a proprietary-blend summary? You can’t reproduce what you can’t see.
• Will I get a manufacturing record complete enough to hand to another qualified manufacturer? Owning the recipe is not the same as being able to make it.
• If I leave, what exactly is mine to take (formula, records, custom components, tooling), and is there a release fee? The answer should be clear and in writing before you commit, not negotiated on the way out.
• Are there any restrictions on where, or with whom, I can manufacture? A portability restriction can lock you in even when you “own” the formula.

Answered plainly and in writing, these tell you whether you’re building an asset or renting a permission. If the answers stay vague, that vagueness is your answer.

About this information

This article is an educational overview for brand owners and operators. It is not legal, regulatory, or medical advice, and it does not create any attorney-client or advisory relationship. Intellectual-property, contract, and dietary-supplement rules change frequently and vary by jurisdiction and by where and how a product is sold. The federal statutes and regulations referenced here (including 18 U.S.C. § 1839, 17 U.S.C. § 101, 35 U.S.C. § 261, and 21 CFR part 111) are cited as of the review date and may be amended, interpreted, or supplemented by state law and marketplace policy. Verify current requirements with qualified counsel or regulatory professionals before acting on anything here. Information is current as of the date last reviewed. Apollo Future Labs supports manufacturing execution and documentation; your counsel decides your ownership, contract, and compliance strategy.